Editorial

Welcome to Pharmacoepidemiology—An Open Access Journal

Cristina Bosetti

Unit of Cancer Epidemiology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy; cristina.bosetti@marionegri.it

We are very proud to launch this new, international, peer-reviewed, open access journal. The main aim of Pharmacoepidemiology [1] is to publish novel and up-to-date research findings, reviews, and communications on the beneficial effects of drugs and their potential adverse effects in humans through epidemiological studies conducted in the real-world on large populations.

Although randomized clinical trials remain the fundamental investigations to provide evidence on drug efficacy and safety, there is an increasing need to integrate this evidence with data from pharmacoepidemiologic studies conducted on large populations of drug users, which provide information on the long-term efficacy and safety and enable better optimization of pharmaceutical products’ uses. Pharmacoepidemiologic studies also have the potential to fill unmet needs in populations generally excluded from clinical trials, such as pregnant women, children, and older adults with several comorbidities, as well as subpopulations with limitations, immigrants, and racialized groups. For this reason, pharmacoepidemiology has been a growing field of research in the few last decades and it is envisioned to make further progress in the near future. This is also thanks to the availability of big data from healthcare electronic records, registries, medical claims, pharmacy data, and wearable and mobile technology, which are routinely collected in several countries worldwide and have provided new opportunities to close the gap between research and clinical care.

This new journal will give space for the publication of studies in this field that are rigorously conducted using proper and innovative (epidemiologic) methods to answer research questions. We are seeking manuscripts that are clearly written, with key findings expressed accessibly. While we do not put a limit on the length of articles, we do encourage conciseness and the full use of supplementary electronic material where appropriate.

All researcher working in the pharmacoepidemiologic field-such as epidemiologists, clinical researchers, pharmacologists, clinicians, and biostatisticians—are welcome to contribute to Pharmacoepidemiology.

Conflicts of Interest: The author declares no conflict of interest.

Reference

Short Biography of Author

Dr. Cristina Bosetti is Head of Unit of Cancer Epidemiology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan. She has a great deal of experience in the conduction and analyses of epidemiological studies on the determinants of cancer and other chronic conditions and has contributed with over 400 peer-reviewed scientific papers on this issue. https://www.marionegri.it/personale/cristina-bosetti, accessed on 6 May 2022.